scholarly journals Long-Term Efficacy and Tolerability of Flutamide Combined with Oral Contraception in Moderate to Severe Hirsutism: A 12-Month, Double-Blind, Parallel Clinical Trial

2007 ◽  
Vol 92 (9) ◽  
pp. 3446-3452 ◽  
Author(s):  
J. Calaf ◽  
E. López ◽  
A. Millet ◽  
J. Alcañiz ◽  
A. Fortuny ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Oral Contraception ◽  
Double Blind ◽  
Term Efficacy

Short‐term efficacy of a gel containing propolis extract, nanovitamin C and nanovitamin E on peri‐implant mucositis: A double‐blind, randomized, clinical trial

2021 ◽  
Author(s):  
José González‐Serrano ◽  
Rosa María López‐Pintor ◽  
Julia Serrano ◽  
Jesús Torres ◽  
Gonzalo Hernández ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Short Term ◽  
Double Blind ◽  
Propolis Extract ◽  
Term Efficacy

CALCIUM, VITAMIN D AND ANABOLIC STEROID IN TREATMENT OF AGED BONES: DOUBLE-BLIND PLACEBO-CONTROLLED LONG-TERM CLINICAL TRIAL

1983 ◽  
Vol 12 (2) ◽  
pp. 124-130 ◽  
Author(s):  
JUKKA INKOVAARA ◽  
GUIDO GOTHONI ◽  
RAIJA HALTTULA ◽  
RAUNO HEIKINHEIMO ◽  
OLAVI TOKOLA
Keyword(s):  
Clinical Trial ◽  
Vitamin D ◽  
Anabolic Steroid ◽  
Double Blind ◽  
Double Blind Placebo

Essential oils in one-stage full-mouth disinfection: double-blind, randomized clinical trial of long-term clinical, microbial and salivary effects

2009 ◽  
Vol 36 (4) ◽  
pp. 333-342 ◽  
Author(s):  
Sheila Cavalca Cortelli ◽  
José Roberto Cortelli ◽  
Marinella Holzhausen ◽  
Gilson Cesar Nobre Franco ◽  
Renato Zanotta Rebelo ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Essential Oils ◽  
Randomized Clinical Trial ◽  
Double Blind ◽  
One Stage ◽  
Full Mouth Disinfection

Long-term efficacy and safety of zolpidem extended-release 12.5 mg, in old patients with chronic primary insomnia: a randomized, double-blind, placebo-controlled, parallel-group, multicenter study

2011 ◽  
Vol 26 (S2) ◽  
pp. 1567-1567
Author(s):  
J. Zarra ◽  
L. Schmidt
Keyword(s):  
Extended Release ◽  
Sleep Onset ◽  
Primary Insomnia ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Old Patients ◽  
Double Blind Placebo ◽  
Term Efficacy ◽  
Parallel Group

ObjectiveTo evaluate long-term efficacy and safety of zolpidem extended-release, in old patients for chronic primary insomnia.DesignMulticenter, randomized, double-blind, placebo-controlled, parallel-group.MethodPopulation: Outpatient with aged more of 65 years. Diagnosis: DSM-IV criteria for chronic primary insomnia; Treatment: Single-dose zolpidem extended-release 12.5 mg (n = 128) or placebo (n = 127), self-administered every night.ResultsPatient's Global Impression (PGI) and Clinical Global Impression-Improvement (CGI-I) were assessed every 4 weeks up to six month. Patient Morning Questionnaire (PMQ), recorded daily, assessed subjective sleep measures-sleep onset latency (SOL), total sleep time (TST), number of awakenings (NAW), wake time after sleep onset (WASO), and quality of sleep (QOS)-and next-day functioning. Zolpidem extended-release also was statistically significantly superior to placebo at every time point for PGI (Items 1–4) and CGI-I (P < 0.0001, rank score), TST, WASO, QOS (P < 0.0001), and SOL (P < or = 0.0014); NAW (Months 2–6; P < 0.0001). Sustained improvement (P < 0.0001, all time points) was observed in morning sleepiness and ability to concentrate (P = 0.0014, month 6) with zolpidem extended-release compared with placebo. Most frequent adverse events for zolpidem extended-release were headache, anxiety and somnolence to the morning. No rebound effect was observed during the first 3 nights of discontinuation.ConclusionsThese findings establish the efficacy of dosing of zolpidem extended-release 12.5 mg for up to 6 months. Treatment provided sustained and significant improvements in sleep onset and maintenance and also improved next-day concentration and morning sleepiness.

Sign in / Sign up

Export Citation Format

Share Document